(Q33754341)

29 July 2017

1 reference

title

In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections (English)

1 reference

29 July 2017

Finegold SM

1

1 reference

29 July 2017

publication date

1 August 1999

1 reference

International Journal of Antimicrobial Agents

29 July 2017

published in

1 reference

29 July 2017

volume

12 Suppl 1

1 reference

29 July 2017

page(s)

S9-14; discussion S26-7

1 reference

Beta-lactamases: current situation and clinical importance.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Beta-lactam resistance in anaerobic bacteria: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

A retrospective review of cases of anaerobic empyema and update of bacteriology

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Resistance to beta-lactam antibiotics in anaerobic bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

beta-lactamase production by oral pigmented Prevotella species isolated from young children

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Phylogenetic characterization and proposal of a new pigmented species to the genus Prevotella: Prevotella pallens sp. nov.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Recently described clinically important anaerobic bacteria: medical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Mechanisms of resistance to β-lactam antibiotics in Acinetobacter calcoaceticus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900086-2

7 January 2021

10.1016/S0924-8579(99)00086-2

Identifiers

DOI

1 reference

29 July 2017

1 reference